Dr. Suiqing Zhou, a PhD student at Nanjing Medical University, is a clinician-scientist specializing in translational liver cancer research. With extensive experience in both clinical and basic science, Dr. Zhou has contributed significantly to hepatocellular carcinoma studies, serving as a key investigator in multiple national and provincial research projects. Their work has been published in high-impact SCI-indexed journals, advancing knowledge in tumor biology, immunotherapy, and metabolic regulation. Dr. Zhou’s research has directly informed innovative diagnostic and therapeutic strategies, demonstrating a commitment to improving liver cancer outcomes. Their contributions reflect a strong dedication to scientific excellence and medical advancement.
Profile
Scopus
Early Academic Pursuits 🎓
Dr. Suiqing Zhou embarked on an academic journey with a deep-rooted passion for medical sciences, particularly in hepatology and translational cancer research. During their undergraduate years, Dr. Zhou demonstrated exceptional aptitude in biomedical sciences, excelling in coursework and laboratory research. Their keen interest in understanding the complexities of liver diseases led them to pursue advanced studies at Nanjing Medical University, a premier institution known for cutting-edge medical research.
With a strong foundation in clinical medicine and biomedical research, Dr. Zhou continued to expand their expertise by engaging in rigorous doctoral studies. Their PhD research primarily focuses on unraveling the molecular mechanisms of hepatocellular carcinoma (HCC), one of the deadliest forms of liver cancer. By integrating clinical observations with laboratory-based investigations, Dr. Zhou has contributed to significant breakthroughs in understanding cancer metabolism and therapeutic resistance.
Professional Endeavors 💼
As a clinician-scientist, Dr. Zhou seamlessly bridges the gap between medical practice and scientific inquiry. While undergoing extensive clinical training, they also immersed themselves in high-impact research projects, gaining recognition as a Principal Investigator and key contributor to several national and provincial-level research initiatives.
Dr. Zhou’s expertise extends beyond traditional clinical practice; they have played a pivotal role in advancing translational medicine by incorporating cutting-edge technologies such as CRISPR gene editing, omics-based studies, and immune profiling. Their ability to translate laboratory findings into potential therapeutic strategies has led to collaborations with leading hepatology research centers and biotechnology firms.
Contributions and Research Focus 🎡
Dr. Zhou’s research is primarily centered on elucidating the biological pathways that drive hepatocellular carcinoma progression. Key areas of investigation include:
- Cancer Metabolism and Fatty Acid Biosynthesis: Their research on eIF3f-mediated fatty acid biosynthesis remodeling has provided new insights into tumor malignancy and potential metabolic targets for therapy.
- Tumor Angiogenesis and Immune Evasion: By studying the role of DGKG in endothelial cells, Dr. Zhou has identified critical mechanisms underlying HCC’s ability to evade immune responses and sustain aggressive growth.
- Ferroptosis Sensitivity and Immunotherapy Augmentation: Through CRISPR/Cas9 screening, Dr. Zhou’s team has pinpointed TRIM34 as a crucial regulator of ferroptosis sensitivity, paving the way for novel combination therapies to enhance immunotherapy efficacy.
- Biomarker Discovery and Personalized Medicine: Their research on GFPT2 and CRTC2 as novel biomarkers has opened new avenues for early diagnosis and tailored treatment approaches in HCC.
Dr. Zhou’s impressive publication record (9 SCI-indexed articles) in top-tier journals, including Journal of Hepatology, Cancer Letters, British Journal of Cancer, and Cell Metabolism, underscores the impact of their research in the global scientific community.
Accolades and Recognition 🏆
Dr. Zhou’s contributions to liver cancer research have been met with well-deserved recognition. Their innovative work has led to one published patent (ZL 2021 1 0367998.9, China), signifying their role in developing novel diagnostic and therapeutic solutions.
Beyond research, Dr. Zhou has been actively involved in academic publishing as an editorial board member, further solidifying their reputation as a thought leader in oncology and translational medicine. Invitations to review manuscripts for prestigious medical journals highlight their expertise and influence in the field.
Impact and Influence 🔄
The impact of Dr. Zhou’s research extends beyond publications and patents—it has directly contributed to the refinement of clinical protocols for liver cancer management. Their findings have influenced treatment guidelines and inspired ongoing clinical trials aimed at improving patient outcomes.
Additionally, Dr. Zhou’s role as a mentor and educator has fostered the next generation of medical researchers. By engaging in academic teaching and research supervision, they have guided young scholars in navigating complex biomedical challenges, ensuring a legacy of scientific excellence.
Legacy and Future Contributions 💡
Looking ahead, Dr. Zhou aspires to expand their research on precision oncology, integrating AI-driven diagnostics and targeted therapies into hepatology. Their future endeavors include:
- Developing Next-Generation Biomarker Panels: Enhancing early detection strategies for liver cancer through advanced molecular profiling.
- Exploring AI-Driven Drug Discovery: Utilizing artificial intelligence to identify novel drug targets and optimize personalized treatment plans.
- Expanding Global Collaborations: Partnering with leading hepatology research institutions to accelerate translational research efforts.
Dr. Zhou’s relentless pursuit of knowledge and unwavering commitment to medical innovation position them as a driving force in the field of liver cancer research. With a distinguished career marked by scientific breakthroughs and impactful contributions, their work continues to inspire hope for improved cancer treatments and patient care worldwide.
Publication Top Notes
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma. Journal of Hepatology
Author: Zhang L, Xu J, Zhou S, Yao F, Zhang R, You W, Dai J, Yu K, Zhang Y, Baheti T, Pu L, Xu J, Qian X, Zhang C, Xia Y, Dai X, Li Q, Wang X.
Journal: Journal of Hepatology
Year: 2024
Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma
Author: Y., Gao, Yun, X., Chen, Xiaoyun, Y., Zhu, Yuerong, … L., Pu, Liyong, X., Wang, Xuehao
Journal: Human Cell
Year: 2025